ERBB2 and gastric cancer: HER2 targeted therapy and anti-angiogenic treatment in combination with chemotherapy represent well-established therapeutic strategies in stage IV gastric cancer, and immune checkpoint blockade is rapidly evolving as a therapeutic strategy as well.